Maze Therapeutics Inc
MAZE8.210
+0.510+6.62%
Cierre 04/25, 16:00（ET）Cotizaciones retrasadas 15 min
--Cap. mercado
--P/E TTM
Más Datos de Maze Therapeutics Inc Compañía
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Información de la empresa
Código de la empresaMAZE
Nombre de la empresaMaze Therapeutics Inc
Fecha de salida a bolsaJan 31, 2025
Fundada en2017
Director ejecutivoDr. Jason V. Coloma, Ph.D.
Número de empleados125
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección171 Oyster Point Boulevard, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono16508505070
Sitio Webhttps://www.mazetx.com/
Código de la empresaMAZE
Fecha de salida a bolsaJan 31, 2025
Fundada en2017
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 27 de abr
Hora de actualización: dom., 27 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Estadísticas de accionistas
Accionista
Proporción
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Tipo
Accionista
Proporción
Venture Capital
27.81%
Private Equity
12.90%
Investment Advisor/Hedge Fund
8.50%
Hedge Fund
6.90%
Individual Investor
5.91%
Corporation
5.51%
Investment Advisor
2.60%
Family Office
1.10%
Other
28.77%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
16
30.56M
69.78%
+23.42M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Third Rock Ventures, LLC
12.79M
29.2%
+5.76M
+82.04%
Feb 03, 2025
ARCH Venture Partners
4.12M
9.41%
+4.12M
--
Jan 31, 2025
Deep Track Capital LP
3.02M
6.9%
+3.02M
--
Jan 31, 2025
Matrix Capital Management Company, LP
2.49M
5.68%
+2.49M
--
Jan 31, 2025
Foresite Capital Management, LLC
2.46M
5.61%
+2.46M
--
Jan 31, 2025
Alphabet Holdings L.L.C.
2.41M
5.51%
+2.41M
--
Jan 31, 2025
Brush (James)
1.63M
3.73%
+1.63M
--
Jan 31, 2025
The Vanguard Group, Inc.
49.15K
0.11%
+348.00
+0.71%
Feb 28, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos